Gabriella Björknert Caracciolo has today announced that she will leave the role as CFO and deputy CEO for Bactiguard Holding AB (publ)
“Gabriella is a key person in the company and she has made an impactful contribution to establishing the platform for our continued expansion. While I regret that she has chosen to leave Bactiguard I respect her decision to return to the financial sector. I want to thank her for her significant contributions to the company and wish her all the best for the future ", says Anders Göransson, CEO of Bactiguard.
“My time at Bactiguard has been both exciting and challenging. It has been a privilege to be part of laying the foundation for the company's growth journey and transformation, and I am convinced that Bactiguard will continue to strengthen its position as the infection prevention leader going forward ", says Gabriella Björknert Caracciolo, CFO and deputy CEO of Bactiguard, who is joining Söderberg & Partners as COO.
The recruitment process to find a replacement will start immediately.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2021-12-13, at 08:00.
For further information, please contact:
Anders Göransson, CEO, phone: +46 8 440 58 80
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.
Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about Bactiguard www.bactiguard.com
